Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 11/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598925 | 1.00 | TSHR (0.44) | TSHRTAAR1KDM1AMAOAMAOB | |
| SCHEMBL18631046 | 0.84 | TSHR (0.52) | TSHRTAAR1KDM1AMAOAMAOB | |
| SCHEMBL18631044 | 0.84 | TSHR (0.52) | TSHRTAAR1KDM1AMAOAMAOB | |
| SCHEMBL21297456 | 0.84 | TSHR (0.52) | TSHRTAAR1KDM1AMAOAMAOB | |
| SCHEMBL10171785 | 0.82 | TSHR (0.45) | TSHRTAAR1LMNABCHEACHE | |
| SCHEMBL599983 | 0.82 | TSHR (0.45) | TSHRTAAR1LMNABCHEACHE | |
| SCHEMBL599079 | 0.82 | TSHR (0.45) | TSHRTAAR1LMNABCHEACHE | |
| SCHEMBL599977 | 0.82 | TSHR (0.45) | TSHRTAAR1LMNABCHEACHE | |
| SCHEMBL600095 | 0.82 | TSHR (0.45) | TSHRTAAR1LMNABCHEACHE | |
| SCHEMBL10171869 | 0.78 | TSHR (0.41) | TSHRTAAR1LMNABCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114994-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-11 | — | — | US | disclosed |
| US-7495006-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2009-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | HAVCR2, PNP, PCNA | TSHR 3945/4885TAAR1 4000/4885KDM1A 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.